がん治療におけるNDDS市場：タイプ、投与方法、投与経路、用途、エンドユーザー別-2025-2030年の世界予測

がん治療におけるNDDS市場は、2023年に104億1,000万米ドルと評価され、2024年には117億5,000万米ドルに達すると予測され、CAGR 13.28％で成長し、2030年には249億4,000万米ドルに達すると予測されています。

がん治療における新規ドラッグデリバリーシステム（NDDS）は、がん治療に関連する有効性、安全性、患者の経験を改善することを目的とした変革的なアプローチです。これらのシステムは、リポソーム、ナノ粒子、モノクローナル抗体のような先進的な方法を包含し、腫瘍部位への治療薬の標的送達と制御放出を提供し、従来の化学療法によく見られる副作用を最小限に抑えます。NDDSの必要性は、がんの有病率の増加と、より効果的で毒性の少ない治療法に対する切実な要求から生じています。NDDSの最終用途は、精密医療がますます優先されるようになっている病院、診療所、研究機関など、さまざまな最終用途分野に広がっています。

がん治療におけるNDDSの成長を促進する主な要因としては、ドラッグデリバリーシステムの技術進歩、個別化医療に対する意識の高まり、製薬企業による研究開発投資の増加などが挙げられます。さらに、革新的な治療法に対する規制当局の支援や生物製剤の採用増加も市場の可能性を高めています。しかし、市場は高い開発コスト、複雑な規制経路、製品の製造と検証に伴う複雑さといった課題に直面しています。

毒性リスクの軽減が期待される生分解性で生体適合性の高いデリバリーシステムの開発に注力することで、チャンスをつかむことができます。ドラッグデリバリーの精度を高めるために、人工知能や機械学習の統合にイノベーションを向けることもできると思われます。画期的な研究のための学術機関との共同研究は、戦略的な進歩をもたらすことができます。さらに、アンメット・メディカル・ニーズを抱える新興市場への進出は、大きな成長の可能性を秘めています。

しかし、技術的な複雑さや革新的ソリューションの市場投入までの時間の長期化によって、市場の成長が妨げられる可能性もあります。こうした課題を克服するために、利害関係者は継続的な研究開発に投資するとともに、承認プロセスを合理化するために規制機関との強力な協力関係を維持する必要があります。市場のダイナミックな性質は常に適応を必要とし、技術動向を先取りすることが持続的成長と競争力にとって極めて重要になります。

市場力学：急速に進化するがん治療におけるNDDS市場の主要市場インサイトを公開

がん治療におけるNDDS市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のがん有病率の上昇
  • 薬物の溶解性向上と毒性軽減を目的としたNDDSのニーズの高まり
  • がんに対する新規ドラッグデリバリーシステム開発への投資の加速
• 市場抑制要因
  • 限られた認識と莫大なコストの関与
• 市場機会
  • 有利な償還政策と相まって、政府のイニシアティブが台頭
  • 先進的な抗がんナノドラッグデリバリーシステムに関する継続的な研究活動
• 市場の課題
  • 熟練した経験豊富な医療専門家の不足

ポーターの5つの力：がん治療におけるNDDS市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：がん治療におけるNDDS市場における外部からの影響の把握

外部マクロ環境要因は、がん治療におけるNDDS市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析がん治療におけるNDDS市場における競合情勢の把握

がん治療におけるNDDS市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスがん治療におけるNDDS市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、がん治療におけるNDDS市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨がん治療におけるNDDS市場における成功への道筋を描く

がん治療におけるNDDS市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でがんの罹患率が上昇
    • 薬物の溶解性を改善し毒性を軽減するためのNDDSの必要性が高まっている
    • がんに対する新しいドラッグデリバリーシステムの開発への投資を加速
  • 抑制要因
    • 認識不足と莫大なコストへの関与
  • 機会
    • 政府の新たな取り組みと有利な償還政策の組み合わせ
    • 先進的な抗がんナノドラッグデリバリーシステムに関する調査活動
  • 課題
    • 熟練した経験豊富な医療専門家の不足
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 がん治療におけるNDDS市場：タイプ別

• デンドリマー
• リポソーム
• ミセル
• ナノ粒子

第7章 がん治療におけるNDDS市場モード別

• 制御ドラッグデリバリーシステム
• 調節ドラッグデリバリーシステム
• 標的ドラッグデリバリーシステム

第8章 がん治療におけるNDDS市場：投与経路別

• 注射ドラッグデリバリーシステム
• 経口ドラッグデリバリーシステム
• 肺ドラッグデリバリーシステム
• 経皮ドラッグデリバリーシステム

第9章 がん治療におけるNDDS市場：用途別

• 脳腫瘍
• 乳がん
• 肺がん
• 膵臓がん

第10章 がん治療におけるNDDS市場：エンドユーザー別

• 外来手術センター
• 病院
• 専門クリニック

第11章 南北アメリカのがん治療におけるNDDS市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のがん治療におけるNDDS市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのがん治療におけるNDDS市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AstraZeneca
• Boston Scientific Corporation
• Cospheric LLC
• Enable Injections
• GlaxoSmithKline PLC
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Merit Medical Systems
• MO-SCI Corporation
• Novartis AG
• Pacira BioSciences, Inc.
• Pfizer Inc.
• Samyang Holdings Corporation
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• West Pharmaceutical Services, Inc.

LIST OF FIGURES

• FIGURE 1. NDDS IN CANCER THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. NDDS IN CANCER THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. NDDS IN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. NDDS IN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NDDS IN CANCER THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NDDS IN CANCER THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CONTROLLED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MODULATED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ORAL DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PULMONARY DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TRANSDERMAL DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY BRAIN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 48. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 75. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 80. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 166. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 168. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 185. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 186. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 187. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 190. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 191. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 192. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 239. NDDS IN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 240. NDDS IN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The NDDS in Cancer Therapy Market was valued at USD 10.41 billion in 2023, expected to reach USD 11.75 billion in 2024, and is projected to grow at a CAGR of 13.28%, to USD 24.94 billion by 2030.

The Novel Drug Delivery Systems (NDDS) in cancer therapy represent a transformative approach aimed at improving the efficacy, safety, and patient experience associated with cancer treatment. These systems encompass advanced methods like liposomes, nanoparticles, and monoclonal antibodies, offering targeted delivery and controlled release of therapeutic agents at tumor sites, minimizing the adverse effects commonly associated with traditional chemotherapy. The necessity for NDDS arises from the increasing prevalence of cancer and the compelling demand for more effective and less toxic treatment modalities. Its applications extend across various end-use sectors, including hospitals, clinics, and research institutes, where precision medicine is increasingly prioritized.

Key factors driving the growth of NDDS in cancer therapy include technological advancements in drug delivery systems, growing awareness about personalized medicine, and increased R&D investments by pharmaceutical companies. Additionally, regulatory support for innovative treatment options and the rising adoption of biologics are enhancing the market potential. However, the market faces challenges such as high development costs, complex regulatory pathways, and the intricacies involved in product manufacturing and validation.

Opportunities can be seized by focusing on the development of biodegradable and bio-compatible delivery systems, which are anticipated to mitigate risks of toxicity. Innovation could be directed towards the integration of artificial intelligence and machine learning to enhance precision in drug delivery. Collaborations with academic institutions for groundbreaking research can provide strategic advancements. Furthermore, expanding into emerging markets with unmet medical needs presents vast growth potential.

However, the market's growth could be hindered by technological complexities and the prolonged time-to-market for innovative solutions. To navigate these challenges, stakeholders should invest in continuous research and development, while also maintaining strong collaborations with regulatory bodies to streamline approval processes. The dynamic nature of the market requires constant adaptation, and staying ahead of technological trends will be crucial for sustained growth and competitiveness.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving NDDS in Cancer Therapy Market

The NDDS in Cancer Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of cancer across the globe
  • Increasing need of NDDS to imrove drug solubility and reduce toxicity
  • Accelerating investments for development of novel drug delivery systems for cancer
• Market Restraints
  • Limited awareness and involvement of huge cost
• Market Opportunities
  • Emerging government initiatives coupled with favorable reimbursement policies
  • Ongoing research activities for advanced anti-cancer nano drug delivery system
• Market Challenges
  • Dearth of skilled and experienced medical professionals

Porter's Five Forces: A Strategic Tool for Navigating the NDDS in Cancer Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the NDDS in Cancer Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the NDDS in Cancer Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the NDDS in Cancer Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the NDDS in Cancer Therapy Market

A detailed market share analysis in the NDDS in Cancer Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the NDDS in Cancer Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the NDDS in Cancer Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the NDDS in Cancer Therapy Market

A strategic analysis of the NDDS in Cancer Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the NDDS in Cancer Therapy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca, Boston Scientific Corporation, Cospheric LLC, Enable Injections, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Merit Medical Systems, MO-SCI Corporation, Novartis AG, Pacira BioSciences, Inc., Pfizer Inc., Samyang Holdings Corporation, Sanofi S.A., Teva Pharmaceutical Industries Ltd., and West Pharmaceutical Services, Inc..

Market Segmentation & Coverage

This research report categorizes the NDDS in Cancer Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Dendrimers, Liposomes, Micelles, and Nanoparticles.
• Based on Mode, market is studied across Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, and Targeted Drug Delivery Systems.
• Based on Route of Administration, market is studied across Injectable Drug Delivery Systems, Oral Drug Delivery Systems, Pulmonary Drug Delivery Systems, and Transdermal Drug Delivery Systems.
• Based on Application, market is studied across Brain Cancer, Breast Cancer, Lung Cancer, and Pancreatic Cancer.
• Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of cancer across the globe
    • 5.1.1.2. Increasing need of NDDS to imrove drug solubility and reduce toxicity
    • 5.1.1.3. Accelerating investments for development of novel drug delivery systems for cancer
  • 5.1.2. Restraints
    • 5.1.2.1. Limited awareness and involvement of huge cost
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging government initiatives coupled with favorable reimbursement policies
    • 5.1.3.2. Ongoing research activities for advanced anti-cancer nano drug delivery system
  • 5.1.4. Challenges
    • 5.1.4.1. Dearth of skilled and experienced medical professionals
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. NDDS in Cancer Therapy Market, by Type

• 6.1. Introduction
• 6.2. Dendrimers
• 6.3. Liposomes
• 6.4. Micelles
• 6.5. Nanoparticles

7. NDDS in Cancer Therapy Market, by Mode

• 7.1. Introduction
• 7.2. Controlled Drug Delivery Systems
• 7.3. Modulated Drug Delivery Systems
• 7.4. Targeted Drug Delivery Systems

8. NDDS in Cancer Therapy Market, by Route of Administration

• 8.1. Introduction
• 8.2. Injectable Drug Delivery Systems
• 8.3. Oral Drug Delivery Systems
• 8.4. Pulmonary Drug Delivery Systems
• 8.5. Transdermal Drug Delivery Systems

9. NDDS in Cancer Therapy Market, by Application

• 9.1. Introduction
• 9.2. Brain Cancer
• 9.3. Breast Cancer
• 9.4. Lung Cancer
• 9.5. Pancreatic Cancer

10. NDDS in Cancer Therapy Market, by End-User

• 10.1. Introduction
• 10.2. Ambulatory Surgical Centers
• 10.3. Hospitals
• 10.4. Specialty Clinics

11. Americas NDDS in Cancer Therapy Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific NDDS in Cancer Therapy Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa NDDS in Cancer Therapy Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AstraZeneca
• 3. Boston Scientific Corporation
• 4. Cospheric LLC
• 5. Enable Injections
• 6. GlaxoSmithKline PLC
• 7. Johnson & Johnson Services, Inc.
• 8. Merck & Co., Inc.
• 9. Merit Medical Systems
• 10. MO-SCI Corporation
• 11. Novartis AG
• 12. Pacira BioSciences, Inc.
• 13. Pfizer Inc.
• 14. Samyang Holdings Corporation
• 15. Sanofi S.A.
• 16. Teva Pharmaceutical Industries Ltd.
• 17. West Pharmaceutical Services, Inc.